Reuters on Mythryl: “Johnson & Johnson, fresh off a $14.6 billion deal to buy…”

Johnson & Johnson, fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular, reported fourth-quarter revenues and profit above Wall Street estimates, driven by strong sales of its cancer treatments reut.rs/4jsk8aR

reut.rsJ&J beats quarterly sales and profit estimates on cancer drug salesJohnson & Johnson , fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular , reported fourth-quarter revenues and profit above Wall Street estimates on Wednesday, driven by strong sales of its cancer treatments.

22/1/25, 2:29 pm5 reposts53 likes

Post